NO20004917L - Farmasøytika for avbildning av angiogene mangler - Google Patents

Farmasøytika for avbildning av angiogene mangler

Info

Publication number
NO20004917L
NO20004917L NO20004917A NO20004917A NO20004917L NO 20004917 L NO20004917 L NO 20004917L NO 20004917 A NO20004917 A NO 20004917A NO 20004917 A NO20004917 A NO 20004917A NO 20004917 L NO20004917 L NO 20004917L
Authority
NO
Norway
Prior art keywords
pharmaceuticals
deficiencies
imaging angiogenic
angiogenic
imaging
Prior art date
Application number
NO20004917A
Other languages
English (en)
Other versions
NO20004917D0 (no
Inventor
Miland Rajopadhye
D Scott Edwards
Thomas David Harris
Stuart J Heminway
Shuang Liu
Prahlad R Singh
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO20004917D0 publication Critical patent/NO20004917D0/no
Publication of NO20004917L publication Critical patent/NO20004917L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20004917A 1998-03-31 2000-09-29 Farmasøytika for avbildning av angiogene mangler NO20004917L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8015098P 1998-03-31 1998-03-31
US11271598P 1998-12-18 1998-12-18
PCT/US1999/006826 WO1999058162A2 (en) 1998-03-31 1999-03-29 Pharmaceuticals for the imaging of angiogenic disorders

Publications (2)

Publication Number Publication Date
NO20004917D0 NO20004917D0 (no) 2000-09-29
NO20004917L true NO20004917L (no) 2000-11-02

Family

ID=26763137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004917A NO20004917L (no) 1998-03-31 2000-09-29 Farmasøytika for avbildning av angiogene mangler

Country Status (20)

Country Link
US (2) US6322770B1 (no)
EP (1) EP1068224B1 (no)
JP (1) JP4487019B2 (no)
KR (1) KR20010042288A (no)
CN (1) CN1295578A (no)
AR (1) AR020586A1 (no)
AT (1) ATE295369T1 (no)
AU (1) AU5541799A (no)
BR (1) BR9909420A (no)
CA (1) CA2324555A1 (no)
DE (1) DE69925262T2 (no)
EA (1) EA200001007A1 (no)
EE (1) EE200000574A (no)
ES (1) ES2241313T3 (no)
HU (1) HUP0101468A2 (no)
IL (1) IL138093A0 (no)
NO (1) NO20004917L (no)
PL (1) PL343804A1 (no)
SK (1) SK13952000A3 (no)
WO (1) WO1999058162A2 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU2001259961A1 (en) * 2000-05-08 2001-11-20 Interuniversitair Micro-Elektronica Centrum Method and technology for high-throughput lead profiling
JP5078212B2 (ja) 2000-06-02 2012-11-21 ブラッコ・スイス・ソシエテ・アノニム 内皮細胞を標的とするための化合物、それを含む組成物およびその使用方法
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
WO2001097860A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
EP1296678A2 (en) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2002004030A2 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
EP1337278A2 (en) 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US7271180B2 (en) * 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP5398945B2 (ja) 2001-04-23 2014-01-29 マリンクロッド エルエルシー ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
MXPA04001113A (es) * 2001-08-08 2004-07-08 Bristol Myers Squibb Pharma Co Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina.
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
CN100356984C (zh) 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
SI2301587T1 (sl) * 2002-03-01 2014-11-28 Dyax Corp. KDR in VEGF/KDR vezavni peptidi in njihova uporaba pri diagnozi
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2003096387A2 (en) * 2002-05-08 2003-11-20 Phoseon Technology, Inc. High efficiency solid-state light source and methods of use and manufacture
US6961607B2 (en) * 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AU2003265898A1 (en) * 2002-09-05 2004-03-29 Genentech, Inc. Infusion catheter having an integrated doppler transducer
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
JP4657721B2 (ja) * 2002-09-19 2011-03-23 センター ナショナル デ ラ レシェルシェ サイエンティフィック（シーエヌアールエス） 新規な誘導システムの合成及び特徴付け、並びに標的細胞への治療対象分子のベクター化
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
WO2004100996A1 (en) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
US20050112064A1 (en) * 2003-08-12 2005-05-26 Sonya Franklin DNA-dependent MRI contrast agents
EP1711203A4 (en) * 2004-01-16 2007-06-13 Barnes Jewish Hospital TARGETED ATHEROSCLEROSIS TREATMENT
DE602005005799T2 (de) * 2004-02-23 2009-04-16 Dow Global Technologies, Inc., Midland Klebstoff auf wasserbasis zum kleben von substraten mit niedriger oberflächenenergie
EP1768558A4 (en) 2004-06-09 2009-11-25 Kereos Inc LIPOPHILES DERIVATIVES OF CHELATE MONOAMIDES
DE602005000853D1 (de) * 2004-07-02 2007-05-24 Vivactis Nv Messung der Wärme erzeugt durch einen chemischen oder biologischen Prozess.
JP2008538204A (ja) * 2005-03-10 2008-10-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 安定化側鎖を含む放射性標識複合体キレート剤
US20090131327A1 (en) * 2005-04-29 2009-05-21 Patrick Doherty Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
WO2007070827A2 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
WO2008042872A1 (en) * 2006-09-29 2008-04-10 Washington University Combinations for treatment of neovasculature
US20100016706A1 (en) * 2006-12-08 2010-01-21 Molecular Image, Inc. Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods
US8194963B2 (en) * 2008-03-10 2012-06-05 Siemens Medical Solutions Usa, Inc. Efficient estimator of pharmacokinetic parameters in breast MRI
AU2009246397B2 (en) 2008-05-13 2013-01-17 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2014160903A2 (en) * 2013-03-27 2014-10-02 Theranos, Inc. Biological sample processing
EP2983721B2 (en) * 2013-04-12 2021-01-20 Evox Therapeutics Limited Therapeutic delivery vesicles
DE102013113156A1 (de) * 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물
US12377166B2 (en) * 2021-08-26 2025-08-05 University Of Washington Iron oxide nanoparticle for targeted chemo-immunotherapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
CA2002860A1 (en) 1988-11-14 1990-05-14 Michael A. Gimbrone Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
CA2028825A1 (en) 1989-04-10 1990-10-11 Thomas J. Brown Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
ATE120374T1 (de) 1989-07-20 1995-04-15 Sandoz Ag Markierte polypeptidderivate.
IN172208B (no) 1990-04-02 1993-05-01 Sint Sa
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
AU7261994A (en) 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
EP0771216B9 (en) 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
MX9801716A (es) 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE69628731T3 (de) * 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
JP2000502050A (ja) 1995-11-14 2000-02-22 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー メタロプロテアーゼ阻害剤としての新規なマクロ環状化合物
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016256A1 (en) * 1996-10-16 1998-04-23 The Burnham Institute Magnetic resonance imaging of thrombi
ES2206689T3 (es) 1996-10-28 2004-05-16 Amersham Health As Agentes de contraste.
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
WO1999013329A1 (en) * 1997-09-10 1999-03-18 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
CA2320339A1 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists

Also Published As

Publication number Publication date
WO1999058162A3 (en) 2000-04-06
PL343804A1 (en) 2001-09-10
EP1068224A2 (en) 2001-01-17
NO20004917D0 (no) 2000-09-29
HUP0101468A2 (hu) 2001-08-28
WO1999058162A2 (en) 1999-11-18
AU5541799A (en) 1999-11-29
DE69925262D1 (de) 2005-06-16
KR20010042288A (ko) 2001-05-25
EA200001007A1 (ru) 2001-04-23
JP2002514611A (ja) 2002-05-21
CA2324555A1 (en) 1999-11-18
SK13952000A3 (sk) 2001-12-03
DE69925262T2 (de) 2006-02-23
BR9909420A (pt) 2001-09-25
US20020001566A1 (en) 2002-01-03
ATE295369T1 (de) 2005-05-15
US6322770B1 (en) 2001-11-27
CN1295578A (zh) 2001-05-16
IL138093A0 (en) 2001-10-31
EP1068224B1 (en) 2005-05-11
JP4487019B2 (ja) 2010-06-23
EE200000574A (et) 2002-10-15
ES2241313T3 (es) 2005-10-16
AR020586A1 (es) 2002-05-22

Similar Documents

Publication Publication Date Title
NO20004917D0 (no) Farmasøytika for avbildning av angiogene mangler
DE69837480D1 (de) Dynamische echtzeit-bildrekonstruktion
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
DE69926878D1 (de) Optoakustisches bildgebungssystem
DE69941532D1 (de) Bildaufnahmesystem
DE69738470D1 (de) Diffraktionsabbildende biosensoren
DE60038155D1 (de) Röntgenbildsystem
DE69839518D1 (de) Spekulum
DE69737936D1 (de) Arzneimittel
NO20010046D0 (no) Dolastatin-15-derivater
DE69928765D1 (de) Inspektionssystem
NO20000231D0 (no) Dolastatin-15-derivater
DK1466615T3 (da) Farmaceutisk præparat
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
DE69715175D1 (de) Bilderzeugung
DE69906880D1 (de) Bilderzeugungsverfahren
NO983828D0 (no) Kontrastmiddel
DE69926012D1 (de) Arzneizubereitungen
DE60017700D1 (de) Bildgebungsverfahren
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
NO20016430L (no) Farmasöytisk kompleks
DE69906934D1 (de) Arzneizubereitungen
DE59804561D1 (de) Lippenrollvorrichtung
DE69901074D1 (de) Bilderzeugungssystem
DK1189600T3 (da) GRF-holdige lyofiliserede farmaceutiske præparater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application